Sagent Pharmaceuticals Private Limited
About Sagent Pharmaceuticals Private Limited
Data last updated:
Sagent Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 April 2023.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U47721MH2023PTC401675.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.5 Cr. It is led by directors Shreekant Krishna Shetty and Hari Om.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹17.08 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹40,842 (net margin 0%) and EBITDA of ₹42.25 Lakh (EBITDA margin 2.5%).
As per MCA filings, the company has open charges of ₹7.5 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address0 – 203 Plot No.26 Matru Smruti L T Colony Road No. 02, Lokmanya Tilak Colony Dadar (E), Mumbai, Maharashtra, India – 400014
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Sagent Pharmaceuticals Private Limited
The main business activity of Sagent Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale and retail trade and repair of motor vehicles and motorcycles.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 45 | Wholesale and retail trade and repair of motor vehicles and motorcycles | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Sagent Pharmaceuticals Private Limited FY 2025 filings available
Sagent Pharmaceuticals Private Limited reported revenue of ₹17.08 Cr (up 434% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Sagent Pharmaceuticals Private Limited
Revenue rose 434% in the latest year. EBITDA rose 34% in the latest year. All are worked out from the filed statements.
Financial Statement Summary of Sagent Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | •••• | •••• |
| Other Income | •••• | •••• |
| Total Revenue | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• |
| Employee Benefit Expense | •••• | •••• |
| Finance Costs | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• |
| Other Expenses | •••• | •••• |
| Total Expenses | •••• | •••• |
| EBITDA | ₹42.25 Lakh | •••• |
| Profit Before Tax | •••• | •••• |
| Tax Expense | •••• | •••• |
| Net Profit (PAT) | ₹40,842 | •••• |
| Balance Sheet | ||
| Share Capital | •••• | •••• |
| Reserves and Surplus | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• |
| Long-term Borrowings | •••• | •••• |
| Short-term Borrowings | •••• | •••• |
| Trade Payables | •••• | •••• |
| Total Liabilities | •••• | •••• |
| Fixed Assets | •••• | •••• |
| Investments | •••• | •••• |
| Inventories | •••• | •••• |
| Trade Receivables | •••• | •••• |
| Cash and Bank Balance | •••• | •••• |
| Total Assets | •••• | •••• |
Financial Ratios of Sagent Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profitability | ||
| EBITDA Margin | 2.5% | •••• |
| Net Profit Margin | 0% | •••• |
| Return on Equity (ROE) | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• |
| Liquidity and Debt | ||
| Current Ratio | •••• | •••• |
| Quick Ratio | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• |
| Efficiency and Growth | ||
| Asset Turnover | •••• | •••• |
| Receivable Days | •••• | •••• |
| Payable Days | •••• | •••• |
| Inventory Days | •••• | •••• |
| Revenue Growth | •••• | •••• |
| Net Profit Growth | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Sagent Pharmaceuticals are in the company report.
Financial statements from FY 2024
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Sagent Pharmaceuticals Private Limited
Sagent Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Appulse Formulations Private Limited | ₹17.11 Cr (FY 2024) | •••• | •••• | •••• | Delhi, India | |
| Glee Biotech Limited | ₹17.11 Cr (FY 2024) | •••• | •••• | -7.0% | •••• | New Delhi, Delhi, India |
| Vamsi Pharma Private Limited | ₹17.11 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Hyderabad, Telangana, India |
| HLL Biotech Limited | ₹17.08 Cr (FY 2024) | •••• | •••• | -68.0% | •••• | Thiruvananthapuram, Kerala, India |
| Octane Biotech Private Limited | ₹17.08 Cr (FY 2025) | •••• | •••• | 1.0% | •••• | Lucknow, Uttar Pradesh, India |
| Sagent Pharmaceuticals Private Limited this company | ₹17.08 Cr (FY 2025) | •••• | •••• | 434.0% | •••• | Mumbai, Maharashtra, India |
| JMM Formulation Private Limited | ₹17.04 Cr (FY 2025) | •••• | •••• | 30.0% | •••• | Kala Amb, Himachal Pradesh, India |
| Anchor Pharma Private Limited | ₹17.02 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Daman, Daman and Diu, India |
| Maksun Biotech Private Limited | ₹16.99 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Panchkula, Haryana, India |
| Elmed Life Sciences Private Limited | ₹16.97 Cr (FY 2025) | •••• | •••• | 48.0% | •••• | Medchal Malkajgiri, Telangana, India |
| Wonset Health Care Private Limited | ₹16.96 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Jaipur, Rajasthan, India |
Peers are the five companies nearest above and the five nearest below Sagent Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Sagent Pharmaceuticals Private Limited
Sagent Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shreekant Krishna Shetty Also directs: Infallible Pharma Private Limited, Mckesson & Robbins Private Limited, Amerisourcebergen Private Limited and 2 more | Director | 25 Apr 2023 | 3 Years 5 Months | Current |
| Hari Om Also directs: Infallible Pharma Private Limited, Mckesson & Robbins Private Limited, Amerisourcebergen Private Limited and 3 more | Director | 25 Apr 2023 | 3 Years 5 Months | Current |
Charges & Borrowings of Sagent Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Nov 2023 | Others | ₹7.5 Cr | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Sagent Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Sagent Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Sagent Pharmaceuticals Private Limited
Sagent Pharmaceuticals Private Limited has 2 board changes on record since 2023: 2 appointments. The latest: Hari Om was appointed as Director on 25 Apr 2023.
Credit Ratings, Litigation & Regulatory Alerts for Sagent Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sagent Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sagent Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Sagent Pharmaceuticals Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sagent Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sagent Pharmaceuticals Private Limited
Sagent Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 25 April 2023 (3+ years old) and is registered under CIN U47721MH2023PTC401675.
Sagent Pharmaceuticals reported revenue of ₹17.08 Cr for FY 2025 (up 434% YoY).
Sagent Pharmaceuticals has 2 current directors:
- Shreekant Krishna Shetty - Director
- Hari Om - Director
Sagent Pharmaceuticals reported a net profit of ₹40,842 (net margin 0%) and EBITDA of ₹42.25 Lakh (EBITDA margin 2.5%) for FY 2025, as per its filed financial statements.
The CIN (Corporate Identification Number) of Sagent Pharmaceuticals is U47721MH2023PTC401675. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sagent Pharmaceuticals was incorporated on 25 April 2023, making it 3+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Sagent Pharmaceuticals by revenue are Appulse Formulations Private Limited, Glee Biotech Limited, Vamsi Pharma Private Limited, HLL Biotech Limited, Octane Biotech Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Hari Om was appointed as Director on 25 Apr 2023. Shreekant Krishna Shetty was appointed as Director on 25 Apr 2023.
The registered office of Sagent Pharmaceuticals is at 0 – 203 Plot No.26 Matru Smruti L T Colony Road No. 02, Lokmanya Tilak Colony Dadar E, Mumbai, Maharashtra, India – 400014.
Sagent Pharmaceuticals has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.5 Cr.
Sagent Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.